Leerink Partners Initiates Coverage On Rapport Therapeutics with Outperform Rating, Announces Price Target of $52

Benzinga Newsdesk www.benzinga.com Positive 64.1%

Neg 0% Neu 0% Pos 64.1%

Leerink Partners analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Outperform rating and announces Price Target of $52.